ES2138272T3 - Utilizacion de esteroides con propiedades antioxidantes para la produccion de preparados farmaceuticos destinados a la sustitucion medicamentosa en un varon. - Google Patents

Utilizacion de esteroides con propiedades antioxidantes para la produccion de preparados farmaceuticos destinados a la sustitucion medicamentosa en un varon.

Info

Publication number
ES2138272T3
ES2138272T3 ES96110339T ES96110339T ES2138272T3 ES 2138272 T3 ES2138272 T3 ES 2138272T3 ES 96110339 T ES96110339 T ES 96110339T ES 96110339 T ES96110339 T ES 96110339T ES 2138272 T3 ES2138272 T3 ES 2138272T3
Authority
ES
Spain
Prior art keywords
steroids
drugs
male
replacement
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96110339T
Other languages
English (en)
Inventor
Michael Prof Dr Oettel
Wolfgang Prof Dr Romer
Doris Dr Hubler
Jens Schroder
Sigfrid Prof Dr Schwarz
Peter Dr Droescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Application granted granted Critical
Publication of ES2138272T3 publication Critical patent/ES2138272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE LA UTILIZACION DE ESTEROIDES CON PROPIEDADES ANTIOXIDATIVAS - 17{AL}-ESTRADIOL O SUS DERIVADOS MODIFICADOS QUIMICAMENTE, O ESTERES DEL 17{AL}-ESTRADIOL O SUS DERIVADOS QUIMICAMENTE MODIFICADOS - PARA LA OBTENCION DE PREPARACIONES FARMACEUTICAS PARA LA SUSTITUCION HORMONAL DE MEDICAMENTOS EN EL HOMBRE. SE MUESTRA LA POSIBILIDAD PARA EL HOMBRE DE UNA TERAPIA DE SUSTITUCION MEDIANTE ESTROGENOS, SIN QUE SE DEN LOS EFECTOS SECUNDARIOS NO DESEADOS PARA EL HOMBRE (POR INTERMEDIO DEL GENOMA) DE UNA CLASICA TERAPIA HORMONAL.
ES96110339T 1995-07-08 1996-06-27 Utilizacion de esteroides con propiedades antioxidantes para la produccion de preparados farmaceuticos destinados a la sustitucion medicamentosa en un varon. Expired - Lifetime ES2138272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19524937A DE19524937A1 (de) 1995-07-08 1995-07-08 Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann

Publications (1)

Publication Number Publication Date
ES2138272T3 true ES2138272T3 (es) 2000-01-01

Family

ID=7766353

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96110339T Expired - Lifetime ES2138272T3 (es) 1995-07-08 1996-06-27 Utilizacion de esteroides con propiedades antioxidantes para la produccion de preparados farmaceuticos destinados a la sustitucion medicamentosa en un varon.

Country Status (7)

Country Link
EP (1) EP0753300B1 (es)
JP (1) JP2765822B2 (es)
AT (1) ATE184795T1 (es)
DE (2) DE19524937A1 (es)
DK (1) DK0753300T3 (es)
ES (1) ES2138272T3 (es)
GR (1) GR3032191T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877169A (en) * 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
DE19821831A1 (de) * 1998-05-15 1999-11-18 Jenapharm Gmbh Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem
IL137727A0 (en) * 1998-02-20 2001-10-31 Jenapharm Gmbh Pharmaceutical preparations for supplementing oestrogen deficiency
US6245756B1 (en) 1998-02-27 2001-06-12 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treatment of estrogen deficiency in the central nervous system
DE19915576A1 (de) * 1999-03-30 2000-10-05 Jenapharm Gmbh Equileninderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
US6589980B2 (en) 2001-05-17 2003-07-08 Wyeth Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents
US7304171B2 (en) 2004-05-27 2007-12-04 Migenix Corp. Compounds and methods for cytoprotection
CN119055659A (zh) * 2024-09-03 2024-12-03 南通大学 17α雌二醇或其化学修饰衍生物在制备预防和/或治疗男性性腺功能低下的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626061A (en) * 1967-09-08 1971-12-07 Upjohn Co Compositions comprising 7{60 -methyl-17{60 -lkylated estradiols
IL107343A (en) * 1992-11-02 2003-10-31 Wyeth Corp PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD LIPID LEVEL, COMPRISING, 17alpha-DIHYDROEQUILENIN
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen

Also Published As

Publication number Publication date
EP0753300B1 (de) 1999-09-22
DE19524937A1 (de) 1997-01-09
DE59603130D1 (de) 1999-10-28
EP0753300A1 (de) 1997-01-15
JPH09100292A (ja) 1997-04-15
GR3032191T3 (en) 2000-04-27
DK0753300T3 (da) 2000-03-27
ATE184795T1 (de) 1999-10-15
JP2765822B2 (ja) 1998-06-18

Similar Documents

Publication Publication Date Title
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
GR3031044T3 (en) Pharmaceutical and/or cosmetic preparation and the use of the preparation
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
DE69535786D1 (de) Modafinil mit definierter Korngrössenverteilung
ES2103563T3 (es) Esteres nitricos con una actividad farmacologica y procedimiento para su preparacion.
AU7076887A (en) Nasal administration of drugs
DE3751845D1 (de) Stabilisiertes Arzneimittel und dessen Herstellung
ES2090317T3 (es) Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
LV11666A (lv) Farmaceitiskie preparati un medikamenti endotelialo traucejumu noversanai un arstesanai
IT9047618A0 (it) Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
IL128724A0 (en) Use of isovaleric acid derivatives for treating spasticity and convulsions
ATE184795T1 (de) Verwendung von steroiden mit antioxidativen eigenschaften zur herstellung von pharmazeutischen präparaten zur medikamentösen substitution beim mann
SI1342473T1 (sl) Topična uporaba estrov vitamina E
CS9001136A2 (en) Method of transdermal therapeutical system's production with active substance's graded liberation and application for active substances' local or systemic administration
ES2086526T3 (es) Aplicacion medicinal de m-csf.
KR950700737A (ko) 기도 염증 및 기도 과잉반응의 치료약품(Medicament for the treatment of airways inflammation and airways hyperresponsiveness)
IT1184729B (it) Prodotti farmaceutico cosmetico,in particolare per la cura di acne e seborrea
ES2187727T3 (es) Medicamentos y cosmeticos que comprenden extractos de zizyphus spina-christi.
ATE230594T1 (de) Topisches arzneimittel auf basis von diclofenac
ATE152911T1 (de) Verwendung von bilobalid und deren derivate zur behandlung von infektionen bei menschen und für eine solche anwendung geeignete pharmazeutische zusammensetzung
ES2146683T3 (es) Uso de bifemelano para la fabricacion de un medicamento para el tratamiento de trastornos hipercineticos.
LV11434A (lv) Augu ekstrakts arstniecibas lidzeklu veterinaras medicinas un kosmetiskas medicinas preparatu izgatavosanai
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 753300

Country of ref document: ES